  Background: Synthetic lethality (SL) refers to the genetic interaction
between two or more genes where only their co-alteration (e.g. by mutations,
amplifications or deletions) results in cell death. In recent years, SL has
emerged as an attractive therapeutic strategy against cancer: by targeting the
SL partners of altered genes in cancer cells, these cells can be selectively
killed while sparing the normal cells. Consequently, a number of studies have
attempted prediction of SL interactions in human, a majority by extrapolating
SL interactions inferred through large-scale screens in model organisms.
However, these predicted SL interactions either do not hold in human cells or
do not include genes that are (frequently) altered in human cancers, and are
therefore not attractive in the context of cancer therapy.
  Results: Here, we develop a computational approach to infer SL interactions
directly from frequently altered genes in human cancers. It is based on the
observation that pairs of genes that are altered in a (significantly) mutually
exclusive manner in cancers are likely to constitute lethal combinations. Using
genomic copy-number and gene-expression data from four cancers, breast,
prostate, ovarian and uterine (total 3980 samples) from The Cancer Genome
Atlas, we identify 718 genes that are frequently amplified or upregulated, and
are likely to be synthetic lethal with six key DNA-damage response (DDR) genes
in these cancers. By comparing with published data on gene essentiality (~16000
genes) from ten DDR-deficient cancer cell lines, we show that our identified
genes are enriched among the top quartile of essential genes in these cell
lines, implying that our inferred genes are highly likely to be (synthetic)
lethal upon knockdown in these cell lines.
